Analysis of how long to take Venetoclax/Venetoclax (Vekela) to see obvious effects

Venetoclax/Venetoclax (Venetoclax) is a selective BCL-2 Inhibitors are mainly used to treat chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and some relapsed or refractory lymphomas. Its mechanism of action is to induce tumor cell apoptosis by inhibiting BCL-2 protein, thereby inhibiting disease progression. Clinically, there are individual differences in the response time of patients to venetoclax, which is closely related to the type of disease, previous treatment history and combined medication regimen.

Generally speaking, for patients with chronic lymphocytic leukemia, when treated with monotherapy or in combination with drugs such as azacitidine and rituximab, most patients can observe improvements in hematological indicators, such as reduction in white blood cell count, shrinkage of lymph nodes, and symptom relief, within the first 1 to 2 months. However, complete response (CR) or deeper molecular response may take 3 to 6 months or even longer, depending on the patient's baseline disease burden and drug resistance.

In the treatment of acute myeloid leukemia, venetoclax is often used in combination with low-dose azacitidine or low-dose chemotherapy to improve efficacy. Clinical data shows that some AML patients can observe improvement in blood levels or remission of myelosuppression in the first treatment cycle (about 28 days), but complete remission still requires 1 to 2 cycles of evaluation. This prompts patients and clinicians to wait patiently when evaluating the efficacy, and at the same time conduct regular blood tests and bone marrow examinations in order to adjust the treatment plan in a timely manner.

In addition, the efficacy of venetoclax is significantly affected by individual factors, including tumorBCL-2 expression levels, concomitant gene mutations, and previous multi-line treatment history. In order to observe the therapeutic effect more quickly, an ascending dose regimen (ramp-up) is often used in clinical practice to gradually reach the target dose to reduce the risk of tumor lysis syndrome while ensuring the efficacy. In summary, the initial efficacy of venetoclax can be seen in most patients in 1 to 2 months, while deep remission usually takes 3 to 6Months, combined medication and individualized dose adjustment can help shorten the response time and improve the therapeutic effect.

Reference materials:https://www.drugs.com/